Efficacy and toxicities of combination maintenance therapy in the treatment of advanced colorectal cancer: a meta-analysis of randomized controlled trials

Fanzhong Lin1, Hongyun Li2*, Jianzhu Wang3, Fang Wang1

1 Department of pathology, Ji’ning first people’s hospital
2 Department of gastroenterology, Ji’ning first people’s hospital
3 Department of internal medicine, Ji’ning first people’s hospital

Corresponding author

Hongyun Li

Department of gastroenterology, Ji’ning first people’s hospital
Ji’ning, Shandong province, 272100, China;
No.11 Jiankang road, Ji’ning, Shandong province, 272100, China
E-mail: hongyunli2018@sohu.com
Tel: +86- 0537-3494722; Fax: +86- 0537-3400763

Running title: the role of combination maintenance therapy in advanced CRC

Word count: 2250
Abstract count: 227
No. of figure: 5
No. of tables: 2

Author contributions

Li H. and Lin F. were responsible for study design. Wang J. and Wang F. were responsible for literature search. Li H. and Wang J. were responsible for data extraction. Lin F., Li H. and Wang F. were responsible for data analysis. Li H. were
responsible for drafting the manuscript. All authors approved the final version of the manuscript.

Conflicts of interest statement
All authors declare that they have no potential conflicts of interests.

Funding
None

Abstract:
Purpose:
We performed a systematic review and meta-analysis to investigate the efficacy and toxicities of combination maintenance therapy for the treatment of advanced colorectal cancer (CRC).

Methods:
Relevant trials were identified by searching electronic databases and conference meetings. Prospective randomized controlled trials (RCTs) assessing combination maintenance therapy in advanced CRC patients were included. Outcomes of interest included overall survival (OS), progression-free survival (PFS) and grade 3-4 toxicities.

Results
A total of 3,174 advanced CRC patients received combination maintenance treatment from 6 RCTs were included for analysis. The use of combination maintenance therapy did not significantly improved PFS (HR 0.95, 95%CI: 0.75-1.20, p=0.67) and OS (HR 1.05, 95%CI: 0.93-1.17, p=0.45) in comparison with single bevacizumab maintenance therapy for the treatment of advanced CRC, similar results were observed in sub-group analysis according to treatment regimens. In addition, combination maintenance therapy significantly improved PFS (HR 0.57, 95%CI: 0.41-0.80, p=0.001), but not for OS (HR 0.93, 95%CI: 0.76-1.14, p=0.47) in comparison with
observation. Additionally, more incidences of any grade 3-4 toxicities (diarrhea, fatigue and hand-foot skin reaction) were observed in the combination maintenance therapy.

**Conclusions:**

The findings of this study show that the efficacy of combination maintenance therapy is comparable to that of bevacizumab alone in terms of PFS and OS for advanced CRC patients, but at the cost of increased grade 3-4 toxicities. Thus single agent bevacizumab remains the recommended maintenance treatment for advanced CRC patients.

**Keywords:** colorectal cancer; maintenance therapy; randomized controlled trials; meta-analysis;

**Introduction**

Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer worldwide, with over 1.2 million new cancer cases and 608,700 deaths estimated to have occurred annually[1]. Nearly one fourth of patients are diagnosed with advanced/metastatic disease, with a 5-year survival of less than 10%[2]. For patients with advanced/metastatic CRC, the treatment goal is to prolong survival and improve quality of life. For patients with advanced CRC, chemotherapy alone yields median survival durations of approximately 20 months [3, 4]. During the past decades, the introduction of novel targeted agents, such as bevacizumab, aflibercept and cetuximab, has modestly improved outcomes in treatment-naïve patients [5-7]. However, additional therapeutic options are needed.

In order to sustain a reduced tumor size and relieve tumor-related symptoms, maintenance therapy has emerged as a novel therapeutic strategy for advanced CRC[8]. Maintenance therapy can be classified into two types: switch maintenance therapy and continuous maintenance therapy. Continuation maintenance is defined as keeping ongoing administration one or more drugs (combination maintenance) used in first-line regimen; while switch maintenance generally introduces an additional agent immediately after completion of four to six cycles of first-line chemotherapy. A previously published meta-analysis has demonstrated that maintenance therapy with
either a continuation or a switch strategy significantly increased progression free survival (PFS, HR 0.56; CI 95% 0.44-0.71, \( p < 0.00001 \)) and time to failure strategies (TFS, HR 0.79; CI 95% 0.7-0.9, \( p = 0.0005 \)) in comparison to observation. Thus, the authors concluded that maintenance therapy should be considered the standard regimen in patients with stage IV colorectal cancer after first line induction therapy. However, to our best knowledge, the role of combination maintenance therapy in the treatment of advanced CRC remains undetermined. As a result, we conduct this systematic review and meta-analysis to assess the overall efficacy and toxicities of combined maintenance therapy in advanced CRC patients.

**Materials and Methods**

**Study Design**

We performed this systematic review and meta-analysis according to the Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines 2009[9].

**Search strategy**

We conducted a comprehensive literature search of public databases including PubMed, EMBASE, Web of Science and the Cochrane library (up to April 30, 2017). Relevant search keywords including the followings: “colorectal cancer,” “maintenance therapy,” and “randomized controlled trials.” No language restriction was administered. An up-to-date search for relevant trials was performed on August 30, 2017. We also conducted a manual search of conference proceedings. All results were input into Endnote X7 reference software (Thomson Reuters, Stamford, CT, US) for duplication exclusion and further reference management.

**Study Selection**

Clinical trials that met the following criteria were included: (1) prospective phase II or III trials involving colorectal patients; (2) trials comparing combination maintenance therapy versus single agent maintenance therapy or observation; and (3) available survival data regarding advanced CRC patients. If multiple publications of the same trial were retrieved or if there was a case mix between publications, only the most recent publication (and the most informative) was included.
**Data Extraction**

Two independent investigators conducted the data abstraction, and any discrepancy between the reviewers was resolved by consensus. The following information was extracted for each study: first author’s name, year of publication, trial phase, number of enrolled subjects, treatment arms, median age, median progression-free survival, and overall survival.

**Outcome measures**

A formal meta-analysis was conducted using Comprehensive Meta Analysis software (Version 2.0). The outcome data were pooled and reported as hazard ratio (HR). The primary outcome of interest was OS and secondary outcomes PFS and any grade 3-4 toxicities in advanced CRC patients.

**Statistical Analysis**

All statistical analyses were performed by using Version 2 of the Comprehensive MetaAnalysis program (Biostat, Englewood, NJ). Between-study heterogeneity was estimated using the $\chi^2$-based Q statistic[10]. The $I^2$ statistic was also calculated to evaluate the extent of variability attributable to statistical heterogeneity between trials. A statistical test with a $p$-value less than 0.05 was considered significant. Study quality was assessed by using the Jadad scale based on the reporting of the studies’ methods and results[11].

**Results:**

**Search results:**

We initially found 160 relevant citations of maintenance therapy in CRC patients. After excluding review articles, phase I studies, case reports, editorial, letters, commentaries, meta-analyses and systematic review (figure 1), we selected 6 randomized controlled trials for analysis [12-17]. Table 1 listed the baseline characteristics of patients and studies. The quality of each included study was roughly assessed according to Jadad scale, and all of the included randomized controlled trials were open-label controlled trials, thus had Jadad score of 3.

**Combination versus single agent maintenance therapy**

Five randomized controlled trials with six comparisons reported PFS data of
combination versus single agent maintenance therapy in advanced CRC patients [12-15, 17]. The pooled hazard ratio for PFS demonstrated that the combination maintenance therapy in advanced CRC patients did not significantly improved PFS giving HR 0.95 (95%CI: 0.75-1.20, \( p=0.67 \), figure 2), in comparison with single bevacizumab maintenance therapy. There was significant heterogeneity between trials (\( I^2=80.3\% \), \( p=0.001 \)), and the pooled HR for PFS was performed by using random-effects model. We the performed sub-group analysis according to treatment regimens, and found that both chemotherapy plus bevacizumab (HR 0.911, 95%CI: 0.63-1.32, \( p=0.62 \)) or EGFR tyrosine kinase inhibitors plus bevacizumab (HR 0.98, 95%CI: 0.72-1.32, \( p=0.88 \)) did not significantly improved PFS in comparison with bevacizumab alone.

Five randomized controlled trials with six comparisons reported OS data of combination versus single agent maintenance therapy in advanced CRC patients [12-15, 17]. The pooled hazard ratio for OS demonstrated that the combination maintenance therapy in advanced CRC patients did not improved OS giving HR 1.05 (95%CI: 0.93-1.17, \( p=0.45 \), figure 3), in comparison with single bevacizumab maintenance therapy. There was moderate heterogeneity between trials (\( I^2=78.1\% \), \( p=0.003 \)), and the pooled HR for OS was performed by using random-effects model. We the performed sub-group analysis according to treatment regimens, and found that both chemotherapy plus bevacizumab (HR 1.04, 95%CI: 0.92-1.18, \( p=0.49 \)) or EGFR tyrosine kinase inhibitors plus bevacizumab (HR 1.06, 95%CI: 0.75-1.20, \( p=0.74 \)) did not improved OS in comparison with bevacizumab alone.

**Combination maintenance therapy versus observation**

Two included trials comparing combination maintenance therapy versus observation reported survival data [15, 16]. The pooled hazard ratio for PFS demonstrated that combination maintenance therapy in advanced CRC patients significantly improved PFS giving HR 0.57 (95%CI: 0.41-0.80, \( p=0.001 \), figure 4), in comparison with observation. However, no survival benefit was observed in combination maintenance in advanced CRC patients (HR0.93, 95%CI: 0.76-1.14, \( p=0.47 \)).

**Toxicities of combination versus single agent maintenance therapy**
Toxicity was particularly relevant in maintenance treatment for advanced CRC, given the potential negative impact on benefit ratio and quality of life. As a result, pooled analysis of reported grades 3 and 4 adverse events (AEs) of interest was performed. There was a significantly increased risk of developing severe non-hematologic toxicities (diarrhea, fatigue, and hand-foot reaction), but not for hypertension, bleeding and thrombosis (table 2).

**Publication bias**

Begg’s funnel plot and Egger’s test were performed to assess the publication bias of literatures. The Begg’s funnel plots did not reveal any evidence of obvious asymmetry (PFS, $p=0.85$; OS, $p=0.57$, figure 5). Then, Egger’s test was used to provide statistical evidence of funnel plot symmetry. The results still did not suggest any evidence of publication bias for PFS ($p=0.74$) and OS ($p=0.77$).

**Discussion**

Due to the addition of novel biological agents to first-line chemotherapy in advanced colorectal cancer patients, the prognosis of advanced CRC patients has been significantly improved [18-20]. However, the optimal duration of first-line treatment remains a controversial issue [21]. Continuous long-term chemotherapy would inevitably increase the side effects associated with chemotherapy and potentially induce the development of drug resistance. On the other hand, intermittent treatment is likely to adversely impact the chemotherapeutic efficacy and treatment outcomes. Two previously meta-analyses have found that maintenance therapy in advanced CRC patients significantly improved PFS and OS in comparison with observation [22, 23]. Before the present study, Dr. Xu et al [24] performed a meta-analysis of three randomized controlled trials to assess the overall efficacy and toxicities of bevacizumab in combination with erlotinib as maintenance therapy in advanced CRC patients, and found that the addition of erlotinib to bevacizumab as maintenance therapy significantly increased overall survival and progression-free survival with an increased but manageable toxicity in CRC patients. However, there is a major error in the meta-analysis analysis, thus the pooled results could be wrong. In fact, the trial
conducted by Hagman et al [25] found that bevacizumab plus erlotinib decreased OS in comparison with bevacizumab alone (median OS, 20.6 versus 30.7; HR 0.58, 95%CI: 0.34-1.01, p=0.051), and the authors should recalculated the HR values for meta-analysis. In addition, there would be a significantly heterogeneity among included the trials, and the pooled the results should be performed by random effect model. As a result, the role of combination maintenance therapy in advanced CRC patients remains unknown.

A total of 3,174 advanced CRC patients received combination maintenance treatment from 6 RCTs were included for analysis. The use of combination maintenance therapy did not significantly improved PFS (HR 0.95, 95%CI: 0.75-1.20, p=0.67) and OS (HR 1.05, 95%CI: 0.93-1.17, p=0.45) in comparison with single bevacizumab maintenance therapy for the treatment of advanced CRC, similar results were observed in sub-group analysis according to treatment regimens. In addition, combination maintenance therapy significantly improved PFS (HR 0.57, 95%CI: 0.41-0.80, p=0.001), but it does not translate into survival benefits (HR 0.93, 95%CI: 0.76-1.14, p=0.47) in comparison with observation. Additionally, more incidences of any grade 3-4 toxicities (diarrhea, fatigue and hand-foot skin reaction) were observed in the combination maintenance therapy, although no significant risk difference of hypertension, bleeding and thrombosis was found between the two groups. Based on our findings, the efficacy of combination maintenance therapy is comparable to that of bevacizumab alone in terms of PFS and OS for advanced CRC patients, but at the cost of increased grade 3-4 toxicities. Thus single agent bevacizumab remains the recommended maintenance treatment for advanced CRC patients.

Give only modest improvement in PFS or OS obtained from maintenance therapy, quality of life (QOL) is another issue needed to be concerned for patients and physicians. Quidde J. et al [26] reported the quality of life assessment in CRC patients receiving maintenance therapy by using EORTC QLQ-C30 and found that continuation of an active maintenance treatment with combination maintenance therapy after induction treatment was neither associated with a detrimental effect on general health status and quality-of-life score (GHS/QoL) scores when compared with
both, less active treatment with Bev alone or no active treatment. In addition, Hegewisch-Becker S. et al [15] also reported that no significant differences in the mean value of GHS/QoL score between combination and single agent maintenance therapy.

Several limitations are needed to be concerned in the present analysis. First of all, this is a meta-analysis at study level. We could not obtain individual patient data from the publication, thus we could not incorporate patients variables into the analysis. For instance, advanced CRC patients are more likely to have received biological agents, and we are unable to investigate whether the survival benefit is similar in advanced CRC patients with or without previously biological agents. Second, there is moderate heterogeneity among the included studies, because different treatment regimens are included for analysis, although we perform sub-group analysis according to treatment regimens. Thirdly, switch and continuous maintenance therapies are combined in the meta-analysis, which might increase the heterogeneity among included trials. Finally, in the meta-analysis of published studies, publication bias is important because trials with positive results are more likely to be published and trials with null results tend not to be published. Our research detects no publication bias using Begg’s and Egger’s tests for OS and PFS.

**Conclusion**

In conclusion, this is the most comprehensive meta-analysis specifically assessing the efficacy and toxicities of combination maintenance therapy in the treatment of advanced CRC patients. The results of our study suggest that efficacy of combination maintenance therapy is comparable to that of bevacizumab alone in advanced CRC patients who have not progressed after at least four cycles of platinum-based chemotherapy, but at the cost of increased grade 3-4 toxicities. Thus single agent bevacizumab remains the recommended maintenance treatment for advanced CRC patients.
References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.

2. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, 3rd, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK et al: The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007, 12(1):38-50.

3. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22(2):229-237.

4. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S: Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006, 24(21):3347-3353.

5. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005, 23(15):3502-3508.

6. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21(1):60-65.

7. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012, 30(28):3499-3506.

8. Kasi PM, Grothey A: Chemotherapy Maintenance. Cancer journal (Sudbury, Mass) 2016, 22(3):199-204.

9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj 2009, 339:b2700.

10. Zintzaras E, Ioannidis JP: Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005, 28(2):123-137.
11. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? *Lancet* 1998, 352(9128):609-613.

12. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P et al: A randomized phase III B trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. *J Clin Oncol* 2009, 27(5):672-680.

13. Diaz-Rubio E, Gomez-Espana A, Massuti B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martinez de Prado P, Gallen M et al: First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. *Oncologist* 2012, 17(1):15-25.

14. Johnsson A, Hagman H, Frodin JE, Berglund A, Keldsen N, Fernebro E, Sundberg J, De Pont Christensen R, Garm Spindler KL, Bergstrom D et al: A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. *Ann Oncol* 2013, 24(9):2335-2341.

15. Hegewisch-Becker S, Graeven U, Lerchenmuller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J et al: Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. *Lancet Oncol* 2015, 16(13):1355-1369.

16. Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM et al: Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. *Lancet* 2015, 385(9980):1843-1852.

17. Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mesange P, Lledo G, Viret F, Ramee JF, Tubiana-Mathieu N et al: Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2015, 16(15):1493-1505.

18. Ciombor KK, Bekaii-Saab T: A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. *Oncologist* 2018, 23(1):25-34.

19. Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S: FOLFIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. *JAMA oncology* 2017, 3(7):e170278.

20. Botrel TEA, Clark LGO, Paladini L, Clark OAC: Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. *BMC Cancer* 2016, 16:677.

21. Rogowski W, Sulzyc-Biellcia V: Optimal duration of a first-line palliative chemotherapy in disseminated colorectal cancer - a review of the literature from a developing country perspective. *Contemporary oncology* 2016, 20(3):210-214.

22. Tamburini E, Rudnas B, Santelmo C, Drudi F, Gianni L, Nicoletti SV, Ridolfi C, Tassinari D: Maintenance based Bevacizumab versus complete stop or continuous therapy after
induction therapy in first line treatment of stage IV colorectal cancer: A meta-analysis of randomized clinical trials. *Crit Rev Oncol Hematol* 2016, 104:115-123.

23. Zhao L, Wang J, Li H, Che J, Cao B: Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer. *Oncotarget* 2016, 7(22):33418-33428.

24. Xu W, Gong Y, Kuang M, Wu P, Cao C, Chen J, Tang C: Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis. *Clin Drug Invest* 2017, 37(2):155-165.

25. Hagman H, Frodin JE, Berglund A, Sundberg LW, Albertsson M, Fernebro E, Johnsson A: A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. *Ann Oncol* 2016, 27(1):140-147.

26. Quidde J, Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Lange T, Dietrich G, Stoehlmacher J, Reinacher A, Tannapfel A, Trarbach T, Marschner N, Schmoll HJ, Hinke A, Al-Batran SE, Arnold D: Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. *Ann Oncol* 2016;27(12):2203-2210.

Figure legend:

Figure 1 Studies eligible for inclusion in the meta-analysis

Figure 2 Random-effect Model of hazard ratio (95%CI) of PFS in advanced CRC patients treated combined maintenance therapy versus single agent maintenance

Figure 3 Random-effect Model of hazard ratio (95%CI) of OS in advanced CRC patients treated combined maintenance therapy versus single agent maintenance

Figure 4 Fixed-effect Model of hazard ratio (95%CI) of OS and PFS in advanced CRC patients treated combined maintenance therapy versus observation

Figure 5 funnel plot for publication bias
| authors          | phase | total | induction regimen | maintenance regimen | No. of patients | median age (years) | median PFS | median OS | Jadad Score |
|------------------|-------|-------|-------------------|---------------------|-----------------|-------------------|------------|-----------|-------------|
| Hecht J.R. et al/2009 | III   | 82    | FOLFOX            | Panitumab +bevacizumab | 413             | 61                | 10         | 19.4      | 3           |
|                  |       |       |                   | bevacizumab         |                 |                   |            |           |             |
|                  |       |       |                   | bevacizumab         | 410             | 62                | 11.4       | 24.5      |             |
|                  | 23    |       | FOLFIRI           | Panitumumab +bevacizumab | 115             | 60                | 10.1       | 20.7      | 3           |
|                  | 0     |       |                   | bevacizumab         | 115             | 59                | 11.7       | 20.5      |             |
| Diaz-rubio E. et al/2012 | III   | 48    | Xelox+bevacizumab | Xelox+bevacizumab  | 239             | 63                | 10.4       | 23.2      | 3           |
|                  | 0     |       |                   | bevacizumab         | 241             | 64                | 9.66       | 19        |             |
| Johnsson A. et al/2013 | III   | 15    | Bevacizumab +chemotherapy | Bevacizumab +erlotinib | 80             | 64                | 5.7        | 21.5      | 3           |
|                  | 9     |       |                   | bevacizumab         | 79              | 65                | 4.2        | 22.8      |             |
| Hegewisch-Becker S. et al/2015 | III   | 47    | Bevacizumab +chemotherapy | Fluoropyrimidine +bevacizumab | 158             | 64                | 6.3        | 20.2      | 3           |
|                  | 2     |       |                   | Bevacizumab         | 156             | 65                | 4.6        | 21.9      |             |
|                  |       |       |                   | No treatment        | 158             | 66                | 3.5        | 23.1      |             |
| Simkens L.H. et al/2015 | III   | 55    | Bevacizumab +chemotherapy | Bevacizumab +capecitabine | 279             | 64                | 11.7       | 25.9      | 3           |
|                  | 8     |       |                   | Bevacizumab         | 278             | 63                | 8.5        | 22.4      |             |
| Tournigand C. et al/2015 | III   | 45    | Bevacizumab +chemotherapy | Bevacizumab +erlotinib | 224             | 63                | 5.4        | 22.1      | 3           |
|                  | 2     |       |                   | bevacizumab         | 228             | 63                | 4.9        | 24.9      |             |

Abbreviation: PFS, progression-free survival; OS, overall survival; FOLFOX, Oxaliplatin+5-FU/LV; FOLFIRI, Irinotecan+5-FU/LV; Xelox, Oxaliplatin +capecitabine;
Table 2 Outcome of grade 3 or 4 toxicity comparing combination versus single agent maintenance therapy.

| Toxicity                  | Trials | Combination therapy | Single agent | Heterogeneity | RR(95%CI)        | P value |
|---------------------------|--------|---------------------|--------------|---------------|-----------------|---------|
| Grade 3-4 hypertension    | 4      | 37/1071             | 51/1073      | 0.88          | 0.73(0.48-1.10) | 0.13    |
| Grade 3-4 diarrhea        | 5      | 182/1229            | 94/1229      | 0.001         | 2.44(1.24-4.78) | 0.01    |
| Grade 3-4 fatigue         | 3      | 36/701              | 13/701       | 0.38          | 2.45(1.31-4.57) | 0.005   |
| Grade 3-4 hand-foot reaction | 3    | 35/701              | 18/704       | 0.65          | 1.91(1.11-3.29) | 0.02    |
| Grade 3-4 bleeding        | 3      | 1/701               | 4/704        | 0.72          | 0.40(0.08-2.03) | 0.27    |
| Grade 3-4 thrombosis      | 5      | 47/1229             | 41/1229      | 0.42          | 1.14(0.76-1.70) | 0.53    |
Potentially relevant records identified through database searching (160)

Excluded (n=145)
- Duplicated reports;
- Basic researches;
- Phase I trials and single arm II trials;
- Methodologic trial description
- Review articles;
- Case reports;

Full text articles assessed for eligibility (n=15)

Trials excluded (n=9):
- single agent maintenance therapy (n=6);
- systematic review of clinical trials (n=3)

Eligible trials for meta-analysis (n=6)
| Group by regimens | Study name               | Hazard ratio | Lower limit | Upper limit | Z-Value | p-Value |
|-------------------|--------------------------|--------------|-------------|-------------|---------|---------|
| CT+BEV            | Diaz-rubio E. et al/2012 | 1.098        | 0.891       | 1.353       | 0.879   | 0.379   |
| CT+BEV            | Hegewisch-Becker S. et al/2015 | 0.911      | 0.627       | 1.323       | -0.490  | 0.624   |
| CT+BEV            | Hecht J.R. et al/2009 (FOLFOX) | 1.270      | 1.061       | 1.521       | 2.599   | 0.009   |
| CT+BEV            | Hecht J.R. et al/2009 (FOLFIRI) | 1.190     | 0.791       | 1.791       | 0.834   | 0.404   |
| EGFR+BEV          | Johnsson A. et al/2013    | 0.790        | 0.554       | 1.127       | -1.299  | 0.194   |
| EGFR+BEV          | Tournigand C. et al/2015  | 0.780        | 0.678       | 0.897       | -3.475  | 0.001   |
| EGFR+BEV          |                          | 0.978        | 0.722       | 1.323       | -0.146  | 0.884   |
| Overall           |                          | 0.951        | 0.751       | 1.203       | -0.422  | 0.673   |

Hazard ratio and 95% CI
| Group by regimens | Study name                        | Statistics for each study | Hazard ratio | Lower limit | Upper limit | Z-Value | p-Value |
|-------------------|----------------------------------|---------------------------|--------------|-------------|------------|---------|---------|
| CT+BEV            | Diaz-rubic E. et al/2012         |                           | 1.050        | 0.851       | 1.295      | 0.456   | 0.649   |
| CT+BEV            | Hegewisch-Becker S. et al/2015   |                           | 1.040        | 0.896       | 1.208      | 0.514   | 0.607   |
| CT+BEV            |                                  |                           | 1.043        | 0.924       | 1.178      | 0.683   | 0.494   |
| EGFR+BEV          | Hecht J.R. et al/2009 (FOLFOX)   |                           | 1.430        | 1.114       | 1.836      | 2.804   | 0.005   |
| EGFR+BEV          | Hecht J.R. et al/2009 (FOLFIRI)  |                           | 1.420        | 0.770       | 2.619      | 1.123   | 0.262   |
| EGFR+BEV          | Johnsson A. et al/2013           |                           | 0.880        | 0.610       | 1.270      | -0.683  | 0.494   |
| EGFR+BEV          | Tournigand C. et al/2015         |                           | 0.790        | 0.630       | 0.990      | -2.044  | 0.041   |
| Overall           |                                  |                           | 1.062        | 0.751       | 1.501      | 0.338   | 0.735   |
|                   |                                  |                           | 1.045        | 0.932       | 1.173      | 0.757   | 0.449   |
### Study name

| Study name                  | Statistics for each study | Hazard ratio and 95% CI |
|-----------------------------|---------------------------|-------------------------|
|                            | Hazard ratio  | Lower limit  | Upper limit | Z-Value | p-Value |
| Hegewisch-Becker S. et al/2015 | 0.480         | 0.374        | 0.616       | -5.755  | 0.000   |
| Simkens L.H. et al/2015     | 0.670         | 0.557        | 0.806       | -4.253  | 0.000   |
|                            | 0.573         | 0.414        | 0.795       | -3.343  | 0.001   |

#### PFS

- 0.1 0.2 0.5 1 2 5 10
- Favours combination
- Favours observation

### Study name

| Study name                  | Statistics for each study | Hazard ratio and 95% CI |
|-----------------------------|---------------------------|-------------------------|
|                            | Hazard ratio  | Lower limit  | Upper limit | Z-Value | p-Value |
| Hegewisch-Becker S. et al/2015 | 1.020         | 0.868        | 1.198       | 0.241   | 0.809   |
| Simkens L.H. et al/2015     | 0.830         | 0.681        | 1.012       | -1.846  | 0.065   |
|                            | 0.928         | 0.759        | 1.135       | -0.729  | 0.466   |

#### OS

- 0.1 0.2 0.5 1 2 5 10
- Favours combination
- Favours observation
